PT - JOURNAL ARTICLE AU - Zachary Ramsay AU - Damian Francis AU - Rachel Bartlett AU - Amza Ali AU - Justin Grant AU - Georgiana Gordon-Strachan AU - Monika Asnani TI - Assessing neuropathic pain in sickle cell disease: How useful is quantitative sensory testing? AID - 10.1101/2021.07.07.21260027 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.07.21260027 4099 - http://medrxiv.org/content/early/2021/07/09/2021.07.07.21260027.short 4100 - http://medrxiv.org/content/early/2021/07/09/2021.07.07.21260027.full AB - Quantitative sensory testing (QST) is a psychophysical test of sensory function which may assist in assessing neuropathic pain (NP). This study compares QST findings with a standardized NP questionnaire to assess their agreement among Jamaicans with sickle cell disease (SCD). A cross sectional study consecutively recruited SCD patients 14 years and older, not pregnant, and without history of clinical stroke or acute illness in Kingston, Jamaica. QST identified thresholds for cold detection, heat detection, heat pain and pressure pain at the dominant thenar eminence, opposite dorsolateral foot and the subject’s most frequent pain site. The Douleur Neuropathique 4 (DN4) was interviewer-administered to diagnose NP. Subjects were divided into low and high sensitization groups if below the 5th and above the 95th percentiles, respectively on QST measures. Kappa agreement coefficients, and receiver operator characteristic (ROC) curves were performed to compare QST with the DN4. Two-hundred and fifty-seven SCD subjects were recruited (mean age 31.7 ± 12.2 years, 55.7% female, 75% SS genotype). Kappa agreements were fair (0.2-0.4) to good (0.6-0.8) between DN4 individual items of itching, hypoesthesia to touch, hypoesthesia to pinprick and brush allodynia with various QST sensitization groups. However, kappa agreements between the NP overall diagnosis on the DN4 with sensitization groups were poor (<0.2). Only heat detection (0.75) and heat pain (0.75) at the leg as a pain site showed satisfactory area under the curve (>0.7). QST may assist in assessing individual components of NP but its use should be limited as a tool to augment clinical assessments.Competing Interest StatementThis study was funded by Avicanna Inc. However, funders were not involved in the actual execution of the study. The authors declare they have no other competing conflicts of interests.Clinical TrialNCT04015401Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04015401 Funding StatementThis study was funded by Avicanna Inc. However, funders were not involved in the actual execution of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of the West Indies Mona Campus Research Ethics Committee (ECP#66, 17/18)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request